Jiangsu Nhwa Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
Jiangsu Nhwa Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has a cash flow conversion efficiency ratio of 0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥425.83 Million ≈ $62.31 Million USD) by net assets (CN¥8.08 Billion ≈ $1.18 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
Cash flow conversion efficiency of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025. This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Jiangsu Nhwa Pharmaceutical Co Ltd for real-time trading data and today's change.
Jiangsu Nhwa Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
Jiangsu Nhwa Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see how much is Jiangsu Nhwa Pharmaceutical Co Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Star Health and Allied Insurance Company Limited
NSE:STARHEALTH
|
-0.032x |
|
Veracyte Inc
NASDAQ:VCYT
|
0.033x |
|
Avient Corp
NYSE:AVNT
|
-0.014x |
|
Liechtensteinische Landesbank AG
SW:LLBN
|
0.034x |
|
Lepu Medical Tech Beijing
SHE:300003
|
0.024x |
|
Hafnia Limited
NYSE:HAFN
|
0.051x |
|
Jiangsu Changshu Rural Commercial Bank Co Ltd
SHG:601128
|
-0.165x |
|
Hiwin Technologies Corp
TW:2049
|
0.050x |
Annual Cash Flow Conversion Efficiency for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025. Review Jiangsu Nhwa Pharmaceutical Co Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.03 Billion ≈ $1.17 Billion |
CN¥1.08 Billion ≈ $157.80 Million |
0.134x | +6.65% |
| 2024-12-31 | CN¥7.27 Billion ≈ $1.06 Billion |
CN¥916.13 Million ≈ $134.06 Million |
0.126x | -19.93% |
| 2023-12-31 | CN¥6.41 Billion ≈ $938.00 Million |
CN¥1.01 Billion ≈ $147.55 Million |
0.157x | +2.01% |
| 2022-12-31 | CN¥5.58 Billion ≈ $817.07 Million |
CN¥861.02 Million ≈ $125.99 Million |
0.154x | +7.85% |
| 2021-12-31 | CN¥4.90 Billion ≈ $717.57 Million |
CN¥701.12 Million ≈ $102.60 Million |
0.143x | -52.98% |
| 2020-12-31 | CN¥4.11 Billion ≈ $600.76 Million |
CN¥1.25 Billion ≈ $182.67 Million |
0.304x | +258.24% |
| 2019-12-31 | CN¥3.60 Billion ≈ $527.50 Million |
CN¥305.97 Million ≈ $44.77 Million |
0.085x | -37.93% |
| 2018-12-31 | CN¥2.96 Billion ≈ $432.87 Million |
CN¥404.52 Million ≈ $59.19 Million |
0.137x | -25.59% |
| 2017-12-31 | CN¥2.46 Billion ≈ $360.17 Million |
CN¥452.35 Million ≈ $66.19 Million |
0.184x | +40.84% |
| 2016-12-31 | CN¥2.12 Billion ≈ $310.80 Million |
CN¥277.14 Million ≈ $40.55 Million |
0.130x | +16.75% |
| 2015-12-31 | CN¥1.83 Billion ≈ $267.39 Million |
CN¥204.24 Million ≈ $29.89 Million |
0.112x | -26.13% |
| 2014-12-31 | CN¥1.06 Billion ≈ $154.97 Million |
CN¥160.24 Million ≈ $23.45 Million |
0.151x | -34.89% |
| 2013-12-31 | CN¥836.21 Million ≈ $122.36 Million |
CN¥194.33 Million ≈ $28.44 Million |
0.232x | +2.88% |
| 2012-12-31 | CN¥682.44 Million ≈ $99.86 Million |
CN¥154.16 Million ≈ $22.56 Million |
0.226x | +54.92% |
| 2011-12-31 | CN¥556.01 Million ≈ $81.36 Million |
CN¥81.08 Million ≈ $11.86 Million |
0.146x | +9.15% |
| 2010-12-31 | CN¥462.56 Million ≈ $67.69 Million |
CN¥61.79 Million ≈ $9.04 Million |
0.134x | -13.66% |
| 2009-12-31 | CN¥396.00 Million ≈ $57.95 Million |
CN¥61.27 Million ≈ $8.97 Million |
0.155x | +14.38% |
| 2008-12-31 | CN¥343.75 Million ≈ $50.30 Million |
CN¥46.50 Million ≈ $6.80 Million |
0.135x | -57.54% |
| 2007-12-31 | CN¥152.39 Million ≈ $22.30 Million |
CN¥48.55 Million ≈ $7.10 Million |
0.319x | +26.12% |
| 2006-12-31 | CN¥122.67 Million ≈ $17.95 Million |
CN¥30.99 Million ≈ $4.53 Million |
0.253x | +259.29% |
| 2005-12-31 | CN¥125.74 Million ≈ $18.40 Million |
CN¥8.84 Million ≈ $1.29 Million |
0.070x | -- |
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more